Brief: Lexicon Pharmaceuticals Announces Update On Submission Of Additional Data To U.S. FDA
22/09/2025 21:55
Sept 22 (Reuters) - Lexicon Pharmaceuticals Inc LXRX.O: LEXICON PHARMACEUTICALS ANNOUNCES UPDATE ON SUBMISSION OF ADDITIONAL DATA TO U.S. FDA SUPPORTING THE BENEFIT-RISK PROFILE OF ZYNQUISTA® IN TYPE 1 DIABETES LEXICON PHARMACEUTICALS INC - FDA FEEDBACK ON ZYNQUISTA EXPECTED IN Q4 Source text: ID:nGNXb8J16T Further company coverage: LXRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lexicon Pharmaceuticals
See all newsLexicon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Lexicon Pharmaceuticals posts Q2 net loss
Brief: Lexicon Pharmaceuticals Q2 EPS USD -0.07
Lexicon Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview
Lexicon Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview